The compound (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one is supplied as a pharma grade active pharmaceutical ingredient for tablet, capsule, granule, injection, oral and injectable dosage forms. The product model is defined by the stereochemically explicit name; the molecular formula is C30H37F2NO3Si2 and the average molecular weight is 553.80 g/mol. The compound is a bis(trimethylsilyl)-protected azetidin-2-one derivative in which the phenolic and secondary alcohol positions are present as trimethylsilyl ethers. No public pharmacopeial monograph currently describes this silylated derivative; each lot is released under an internal monograph that applies pharmacopeial general chapters for identity, purity, residual solvents, elemental impurities, and microbial quality. The product is intended for use in pharmaceutical manufacturing operations conducted under ICH Q7 and is not represented as a final-dosage-form substitute without formulation-specific development.

The two trimethylsilyl groups replace the free phenolic and secondary alcohol protons of the corresponding free diol, ezetimibe. This substitution removes the exchangeable protons at those positions and introduces hydrolytically labile silicon-oxygen bonds. Storage under inert gas in a tightly closed container is recommended because trimethylsilyl ethers are cleavage-sensitive in the presence of moisture, acid, or base. Desiccated storage at 2–8 °C is applied when prolonged retention is required. The compound should not be exposed to ambient relative humidity above 60% for more than 2 h during dispensing; transfer into a controlled dry area is used for open handling.

What Pharmacopeial Methods Are Applied to This Bis(trimethylsilyl) Azetidin-2-One API?

Because the fully protected derivative is not covered by a single public monograph, the release specification is assembled from general chapter methods that are suitable for a moisture-sensitive, non-ionizable azetidin-2-one. Sample handling during analytical preparation is designed to avoid premature desilylation; aqueous sample diluents are acceptable only when the pH is maintained between 5.0 and 7.0 and the prepared sample is injected within 30 min. The following release specification reference methods are applied.

For HPLC assay and impurity analysis, anhydrous acetonitrile or tetrahydrofuran is used as the sample diluent. The method should avoid aqueous buffers at pH below 4.0 or above 8.0, because silyl ether hydrolysis is acid- and base-catalyzed. If an aqueous component is necessary for the mobile phase, the aqueous phase is buffered to 5.0–7.0 and the column temperature is maintained below 40 °C to reduce on-column degradation.

Elemental impurity control follows ICH Q3D, with testing by inductively coupled plasma mass spectrometry. Silicon is not classified as an elemental impurity requiring control under ICH Q3D; however, the trimethylsilyl groups are structural components and are not considered residual derivatization reagents when the product is released as the protected API. Residual silanol or trimethylsilanol is monitored as a related substance where separation is demonstrated.

Particle Size, Excipient Compatibility, and Hydrolytic Degradation Boundaries

Direct compression is the most viable solid-dosage route for this protected API. The powder is delumped through a 30-mesh sieve with nominal aperture 600 µm and blended in a bin blender or V-blender at 20–25 rpm for 15–20 min. Because the trimethylsilyl ether surface can show triboelectric charging, colloidal silicon dioxide may be incorporated at 0.5%–1.0% w/w as a glidant. Lactose monohydrate and microcrystalline cellulose are compatible diluents. Aqueous wet granulation is not suitable because water drives hydrolytic cleavage of the silyl ether groups to the free diol. If granulation is required, dry granulation by roller compaction is preferred; roll pressure and gap settings are product-specific, though ribbon density is typically maintained between 1.1 and 1.3 g/cm³ for controlled density and subsequent compression.

Excipient incompatibilities are dominated by basic or acidic microenvironmental pH. Ammonio methacrylate copolymers, sodium bicarbonate, and other alkaline excipients should be avoided because they accelerate base-catalyzed desilylation. Crospovidone and starch-based disintegrants can be used only after drying to moisture below 0.5% w/w. High-shear granulation with anhydrous ethanol or isopropanol may be considered when dry granulation cannot achieve the required content uniformity, but residual solvent drying must meet ICH Q3C option 1 limits.

The structural difference produces a pronounced shift in reversed-phase HPLC retention; the bis(trimethylsilyl) derivative elutes later than ezetimibe under identical C18 conditions. Method development therefore requires a higher organic modifier content, commonly above 70% acetonitrile or methanol, to maintain reasonable retention. The absence of free hydroxyl donors also alters solid-state hydrogen-bonding potential compared with the free diol. Published data for this specific protected configuration is limited; therefore, the solid form should be characterized for each lot by differential scanning calorimetry and X-ray powder diffraction if crystallinity affects dissolution or content uniformity.

For tablet and capsule manufacture, the blend is compressed on a rotary tablet press with main compression force in the range of 5–15 kN depending on tooling dimensions and tablet weight. Tablet breaking force is monitored per USP <1217>, and friability is evaluated per USP <1216>. Capsule filling on an automatic dosator or tamping machine is conducted with the powder bed maintained below 30% relative humidity. Desiccant sachets in the packaging are used to control moisture ingress during storage.

When the API Is Processed into Tablet, Capsule, Granule, or Injection Matrices

Injectable formulation work requires non-aqueous or low-water solvent systems because the silyl ether groups are hydrolytically cleaved in aqueous media. Anhydrous dimethylacetamide, dehydrated propylene glycol, or dimethyl sulfoxide can be evaluated for solution formulations, provided residual water in the vehicle is below 0.1%. Terminal moist-heat sterilization is not appropriate because steam promotes desilylation. Sterile filtration through a 0.22 µm PVDF or polytetrafluoroethylene membrane is preferred for solution dosage forms. For suspension injections, the API is jet-milled to D90 ≤20 µm and the vehicle is chosen to minimize water activity.

After reconstitution or dilution, the pH should be maintained between 5.0 and 7.0 to slow hydrolytic degradation. Silyl ether hydrolysis is acid- and base-catalyzed; pH below 4.0 or above 8.0 should be avoided. Injectable-grade lots are tested for bacterial endotoxins and particulate matter. Visible and subvisible particulate counts should comply with Ph. Eur. 2.9.19 and USP <788> for the finished injectable product.

Granule dosage forms are best produced by dry granulation or roller compaction. Aqueous binder solutions are excluded. If solvent granulation is necessary, anhydrous ethanol or isopropanol is used, and the granule moisture content is dried to below 0.5% w/w before compression. Granule flow is characterized by Carr index and Hausner ratio during development; no universal flow specification is applied because the particle size distribution is tailored to the intended tablet or capsule process.

Because published data for this specific silyl-protected configuration is limited, formulation-specific forced degradation studies are required before process validation. No equivalence with the free diol ezetimibe is implied by the structural description provided.